Clinical trials: Paclitaxel
Stage IV Pancreatic Cancer
Gemcitabine+Nab-paclitaxel and FOLFIRINOX and Molecular Profiling for Patients With Advanced Pancreatic Cancer
The Investigators in the PCRT team have developed a therapeutic regimen which attacks both the tumor compartment and the stromal compartment of pancreatic cancer and induces complete responses in a small percentage of patients…
- Trial name
- NCT01488552
- Testing
- Gemcitabine, nab-paclitaxel, FOLFIRINOX
- Where
- 5 sites in United States
- Volunteers
- 60 people
- Sponsor
- Pancreatic Cancer Research Team
Solid Tumor, Breast Cancer
Combination Therapy of F16IL2 and Paclitaxel in Solid Tumour Patients
This Phase Ib/II study is an open label, multicenter study. The study is divided in two parts: Phase I: an open-label, dose escalation study of F16IL2 in combination with paclitaxel for patients with solid tumours, bladder…
- Conditions
- Solid Tumor, Breast Cancer, Metastatic Melanoma, Non-small Cell Lung Cancer (NSCLC)
- Trial name
- NCT01134250
- Testing
- F16IL2 in combination with paclitaxel
- Where
- 5 sites in Italy
- Volunteers
- 48 people
- Sponsor
- Philogen S.p.A.
Recurrent Ovarian Cancer, Platinum-sensitive Ovarian Cancer
Iparomlimab/Tuvonralimab + Standard Chemotherapy and Olaparib in Platinum-Sensitive Recurrent Ovarian Cancer
This is a prospective, open-label, single-arm, multicenter exploratory clinical study designed to evaluate the efficacy and safety of iparomlimab/tuvonralimab (QL1706), a bispecific antibody targeting programmed cell death…
- Trial name
- NCT07454018
- Testing
- Iparomlimab/Tuvonralimab
- Volunteers
- 45 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Breast Cancer
Radiation Therapy Plus Paclitaxel in Treating Patients With Stage IIB or Stage III Breast Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00003050
- Testing
- cyclophosphamide, doxorubicin hydrochloride, paclitaxel
- Where
- 2 sites in United States
- Volunteers
- 46 people
- Sponsor
- University of Southern California
Intestinal Stricture
POISE I Pilot Study
POISE I study is a feasibility study for evaluating the safety and efficacy of DCB.
- Trial name
- POISE (NCT03886324)
- Testing
- GIE Medical Drug Coated Balloon
- Where
- Paraguay
- Volunteers
- 10 people
- Sponsor
- GIE Medical
Breast Cancer Metastatic
A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study
The purpose of this study is to find out the possible anti-cancer effect of pelareorep in combination with chemotherapy [paclitaxel] and avelumab in treating a type of breast cancer called Hormone Receptor positive (HR+)/Human…
- Trial name
- NCT04215146
- Testing
- Paclitaxel, Pelareorep, Avelumab
- Where
- 18 sites in United States
- Volunteers
- 48 people
- Sponsor
- Oncolytics Biotech
Chemotherapy-induced Peripheral Neuropathy, Breast Cancer Metastatic
NR in Chemo-induced Peripheral Neuropathy
The purpose of this single-arm phase II trial is to determine whether nicotinamide riboside (NIAGEN®) prevents the progression of peripheral sensory neuropathy in patients receiving infusions of paclitaxel or nab-paclitaxel for…
- Conditions
- Chemotherapy-induced Peripheral Neuropathy, Breast Cancer Metastatic, Platinum-resistant Recurrent Ovarian Cancer, Head and Neck Cancer Stage IV
- Trial name
- NCT03642990
- Testing
- Nicotinamide Riboside
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- Donna Hammond, PhD
Coronary Restenosis
Per-cutaneous Intervention Based Paclitaxel and Sirolimus-Eluting Versus Bare Stents for the Treatment of de Novo Coronary Lesions (PAINT)
Objectives: PRIMARY OBJECTIVE: To compare the in-stent late loss at 9 months of paclitaxel- and sirolimus- eluting stents with the late loss of bare metal control stents.
- Trial name
- NCT00752362
- Testing
- Milennium Matrix® (Control), Infinnium®, Supralimus®
- Where
- 11 sites in Brazil
- Volunteers
- 280 people
- Sponsor
- Sahajanand Medical Technologies Limited
Ovarian Neoplasms, Endometrial Neoplasms
A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study)
Multicenter, randomized, open-label, phase II clinical study comparing Dostarlimab +/- Bevacizumab with standard chemotherapy in patients with gynecological clear cell carcinoma.
- Conditions
- Ovarian Neoplasms, Endometrial Neoplasms, Uterine Cervical Neoplasms, Vulvar Cancer
- Trial name
- DOVE (NCT06023862)
- Testing
- Dostarlimab, Bevacizumab, Doxorubicin
- Where
- 27 sites in Australia, Hong Kong and 5 more
- Volunteers
- 198 people
- Sponsor
- Yonsei University
Ovarian Cancer
Study Comparing Weekly Versus Every 3 Week Chemotherapy in Patients With Ovarian Cancer
The purpose of this study is to study efficacy and the effects on quality of life in women with ovarian cancer treated with a weekly schedule of chemotherapy with carboplatin and paclitaxel compared to those treated with standard…
- Trial name
- MITO-7 (NCT00660842)
- Testing
- carboplatin, paclitaxel
- Where
- 28 sites in Italy
- Volunteers
- 800 people
- Sponsor
- National Cancer Institute, Naples
Recurrent Ovarian Cancer
Phase IB Trial of LDE225 and Paclitaxel in Recurrent Ovarian Cancer
The purpose of this study is to find out if a new drug, LDE225, is safe and has beneficial effects when combined with paclitaxel in women with platinum resistant ovarian cancer.
- Trial name
- NCT02195973
- Testing
- LDE225
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Alabama at Birmingham
Breast Cancer, CIPN - Chemotherapy-Induced Peripheral Neuropathy
Efficacy and Safety of Hyperbaric Oxygen Therapy in Improving Nab-paclitaxel-Induced Peripheral Neuropathy
The goal of this research is to assess whether hyperbaric oxygen therapy can alleviate the symptoms of Nab-paclitaxel-induced peripheral neuropathy and improve patient-reported quality of life.
- Conditions
- Breast Cancer, CIPN - Chemotherapy-Induced Peripheral Neuropathy, Paclitaxel-induced Peripheral Neuropathy
- Trial name
- NCT07410169
- Testing
- Hyperbaric oxygen treatment, Standard Care (in control arm)
- Where
- 2 sites in China
- Volunteers
- 160 people
- Sponsor
- Guangdong Provincial People's Hospital
Gastric Cancer, HIPEC, Anti-PD-1 Antibody Camrelizumab (SHR-1210), Chemotherapy and Surgery
HIPEC Combined With Camrelizumab, Paclitaxel and S-1 for Conversion Therapy in Patients With Advanced Gastric Cancer With Peritoneal Metastasis
There is no currently available treatment for peritoneal metastasis of gastric cancer. Hyperthermic intraperitoneal chemotherapy (HIPEC) can not only maintain the high concentration of drugs in the abdominal cavity, but also…
- Trial name
- NCT04889768
- Testing
- HIPEC, anti-PD-1 antibody Camrelizumab (SHR-1210), Chemotherapy and Surgery
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Zhejiang Cancer Hospital
Immunotherapy, Analgesia
Effect of Neoadjuvant Anti-PD-1 Immunotherapy on Perioperative Analgesia and Postoperative Delirium
To observe the effect of preoperative anti-PD-1 monotherapy combined with chemotherapy on patients' perioperative pain and opioid analgesia, and evaluate its effect on the incidence and severity of patients' postoperative…
- Conditions
- Immunotherapy, Analgesia, NSCLC, Delirium
- Trial name
- NCT05273827
- Testing
- neoadjuvant immunotherapy, Neoadjuvant chemotherapy
- Where
- 3 sites in China
- Volunteers
- 81 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Oropharyngeal Carcinoma
A Study of Reduced Radiation Therapy With Chemotherapy in People With HPV-Positive Throat Cancer
The researchers are doing this study is to find out if lower doses (given in fewer treatments over a shorter period of time) of radiation therapy in combination with standard-of-care chemotherapy is an effective treatment for…
- Trial name
- NCT06984861
- Testing
- 18F-FMISO PET/CT Scan, Chemoradiation, Questionnaires
- Where
- 7 sites in United States
- Volunteers
- 74 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Coronary Artery Disease
TAXUS IV-SR: Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent
The ultimate goal of a paclitaxel eluting stent system (TAXUS stent) is to prevent restenosis by blunting the initial response to stent implant injury and sustaining the arrested response until vascular healing has taken place.
- Trial name
- NCT00292474
- Testing
- percutaneous coronary intervention
- Where
- United States
- Volunteers
- 1,326 people
- Sponsor
- Boston Scientific Corporation
Esophageal Cancer
Trilaciclib Combined With Concurrent Chemoradiotherapy and Immunotherapy in the Treatment of Esophageal Cancer
This study is a double-arm, randomized, controlled, single-center, phase II clinical trial aimed at evaluating the efficacy and safety of chemoradiotherapy plus immunotherapy with or without Trilaciclib in the treatment of…
- Trial name
- NCT06569459
- Testing
- Trilaciclib Injection [Cosela]
- Where
- China
- Volunteers
- 60 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Breast Cancer
Phase II NCT (Neoadjuvant Chemotherapy) w/ Weekly Abraxane in Combination With Carboplatin & Bevacizumab in Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from…
- Trial name
- NCT00675259
- Testing
- bevacizumab, carboplatin, nab-paclitaxel
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Gastric Cancer Peritoneal Metastasis (GCPM)
A Sequential Trial of Low-Dose Radiotherapy Followed by Concurrent Immunotherapy, Systemic Chemotherapy, and Intraperitoneal Perfusion in Gastric Cancer With Peritoneal Carcinomatosis
This study is a prospective, single-center, open-label, exploratory phase II clinical trial aimed at evaluating the safety, tolerability, and preliminary efficacy of low-dose radiotherapy (LDR) sequentially combined with…
- Trial name
- NCT07784413
- Testing
- low-dose radiotherapy (LDR) sequentially combined with serplulimab, bevacizumab analog, and irinotecan or albumin-bound paclitaxel
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Zhejiang Cancer Hospital
Ovarian Cancer, Fallopian Tube Cancers
PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer
This is a randomized trial evaluating the results of using of PARP inhibitor combined with angiogenesis inhibitor. in patients with homologous recombination deficient primary ovarian cancer, fallopian-tube cancer, or primary…
- Conditions
- Ovarian Cancer, Fallopian Tube Cancers, Primary Peritoneal Cancer
- Trial name
- NCT07472140
- Testing
- PARP inhibitor + Bevacizumab, PARP inhibitor
- Where
- Belarus
- Volunteers
- 120 people
- Sponsor
- N.N. Alexandrov National Cancer Centre